This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amylin Pharmaceuticals To Present Data On BYDUREON™, BYETTA® And SYMLIN® At The American Diabetes Association 2012 Meeting

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it will present data for BYDUREON™ (exenatide extended-release for injectable suspension), the first and only once-weekly diabetes treatment, as well as first-in-class diabetes drugs BYETTA ® (exenatide) injection and SYMLIN ® (pramlintide acetate) injection at the 72 nd Scientific Sessions of the American Diabetes Association (ADA), June 8-12, 2012, in Philadelphia. The Company will also host an investor presentation and webcast on Sunday, June 10 at 7:30 p.m. ET/4:30 p.m. PT.

Amylin will highlight data from 13 abstracts, offering new insights into the clinical utility of BYDUREON, BYETTA and SYMLIN, as well as continued research into the exenatide pipeline. BYETTA will be featured at this year’s Joint ADA/The Lancet Symposium, and additional information on the use of long-acting GLP-1 receptor agonist therapy to improve efficacy, adherence and weight in patients with type 2 diabetes will be presented during a corporate symposium.

“Multiple presentations at this year’s meeting demonstrate the durability of effect and long-term safety and tolerability of BYDUREON and BYETTA, as well as provide important insights into the effect of SYMLIN on glucose targets,” said Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals. “For 25 years, Amylin has been an innovator in diabetes treatment. These studies further demonstrate our commitment to expanding physician and patient choices for improving diabetes management and the lives of the millions of people living with this chronic disease.”

Joint ADA/The Lancet SymposiumJoint ADA/The Lancet Symposium: “Exenatide Twice a Day Versus Glimepiride for Prevention of Glycemic Deterioration in Patients with Type 2 Diabetes with Metformin Failure (EUREXA) – An Open-Label Randomized Controlled Trial” will be presented by Guntram Schernthaner, M.D., on Saturday, June 9 at 8:30 a.m. ET.

Featured Symposium“Long-Acting GLP-1 Receptor Agonist Therapy – Improving Efficacy, Adherence, and Weight in Type 2 Diabetes.” This medical education symposium will provide healthcare professionals information about GLP-1 based therapies as an important option in the treatment of type 2 diabetes, restoring the diminished incretin effect and potentially addressing the decline in beta cell function characteristic of type 2 diabetes. The event will be chaired by John Buse, M.D., with medical and scientific presentations by Ralph DeFronzo, M.D., and David D’Alessio, M.D., on Sunday, June 10 at 5:30 a.m. ET. This symposium is supported by an educational grant from Amylin.

Investor PresentationAmylin will also conduct a webcast on Sunday, June 10 at 7:30 p.m. ET/4:30 p.m. PT for the investment community that will include ADA conference highlights. The presentation will be webcast live through the “Investors” section of Amylin’s corporate website at, and a recording will be made available on the website following the event. To access the live webcast, please log on to Amylin's website approximately 15 minutes prior to the presentation to register, download and install any necessary audio software.

Key Amylin Abstracts at ADA

    Late Breaking Poster: “Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir: Randomized, Open-Label Clinical Trial of Efficacy and Safety in Patients with Type 2 Diabetes Inadequately Controlled With Metformin ± Sulphonylureas” will be presented by Melanie Davies, M.D., during a poster session on Sunday, June 10 from 12 – 2 p.m. ET.

Poster: “Pharmacokinetics and Pharmacodynamics of a New Exenatide Formulation, Exenatide Suspension” will be presented by Leigh MacConell, Ph.D., during a poster session on Saturday, June 9 from 11:30 a.m. – 1:30 p.m. ET.

Poster: “Exenatide Once Weekly Resulted in Sustained Improvement in Glycemic Control with Weight Loss through 4 Years” will be presented by Leigh MacConell, Ph.D., during a poster session on Saturday, June 9 from 11:30 a.m. – 1:30 p.m. ET.

Poster: “Two-Year Use of Exenatide Once Weekly in Type 2 Diabetes Mellitus (T2DM) Patients Taking Thiazolidinedione” will be presented by Michael Trautmann, M.D., during a poster session on Saturday, June 9 from 11:30 a.m. – 1:30 p.m. ET.

Poster: “Exenatide Once Weekly was Associated with Improved Glycemic Control Regardless of Baseline Body Weight” will be presented by Richard Pencek, Ph.D., during a poster session on Saturday, June 9 from 11:30 a.m. – 1:30 p.m. ET.

Poster: “Improved Diabetes Treatment Satisfaction and Weight-Related Quality of Life for Asian Patients Treated with Exenatide Once Weekly Versus Twice Daily” will be presented by Marilyn Boardman, Ph.D., during a poster session on Saturday, June 9 from 11:30 a.m. – 1:30 p.m. ET.


Poster and Guided Audio Poster Tour: “Anti-diabetic Effects of Exenatide and Dapagliflozin in Diabetic Mice” will be presented by Krystyna Tatarkiewicz, Ph.D., at a poster session on Saturday, June 9 from 11:30 a.m. – 1:30 p.m. ET and at a Guided Audio Poster Tour on Monday, June 11 from 12 – 1 p.m. ET.

Poster: “Pramlintide-Induced Shift Towards Euglycemia Based on SMBG Profiles in T2DM” will be presented by Kathrin Herrmann, Ph.D., at a poster session on Saturday, June 9 from 11:30 a.m. – 1:30 p.m. ET.

A full list of all Amylin abstracts being presented at ADA is available at

Amylin will post insights from the conference on its corporate blog, “Building Blocks” at The blog will feature perspectives from Amylin leadership and global experts on key issues facing the diabetes community, and the latest innovations that could shape the future of diabetes care.

About BYDUREON™ (exenatide extended-release for injectable suspension)BYDUREON is the first and only once-weekly medicine to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. It is a once-weekly formulation of exenatide, the active ingredient in BYETTA ® (exenatide) injection, which has been available in the U.S. since June 2005 and is used in nearly 80 countries worldwide. BYDUREON works with the body to help make its own insulin when needed, providing continuous glycemic control with just one dose per week. Using Alkermes plc’s proprietary technology for long-acting medications, the biodegradable microspheres in each dose of BYDUREON provide a controlled release of exenatide throughout the week. BYDUREON was approved in the U.S. in January 2012 and in Europe in June 2011.

BYDUREON is an injectable prescription medicine that may improve blood sugar (glucose) in adults with type 2 diabetes mellitus, and should be used along with diet and exercise. BYDUREON is not recommended as the first medication to treat diabetes.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.01 0.00%
GOOG $682.74 0.00%
FB $99.75 0.00%
YHOO $27.05 0.00%
TSLA $147.99 0.00%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs